Eupraxia Pharmaceuticals to Present at Jefferies Global Healthcare Conference
Event summary
- Eupraxia Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 5:30 PM ET.
- The company will also hold 1x1 meetings with investors on June 3rd and 4th.
- Eupraxia's Diffusphere™ technology focuses on localized, controlled drug delivery for unmet medical needs.
- EP-104GI is in a Phase 1b/2 trial for EoE, while EP-104IAR completed a Phase 2b trial for knee osteoarthritis pain.
The big picture
Eupraxia's participation in the Jefferies Global Healthcare Conference underscores its push to engage with investors amid key clinical milestones. The company's Diffusphere™ technology aims to revolutionize drug delivery, addressing unmet needs in pain, inflammatory diseases, and potentially oncology. Success in these areas could position Eupraxia as a key player in targeted therapeutics, but competition and regulatory hurdles remain critical factors.
What we're watching
- Clinical Progress
- The pace at which Eupraxia advances its Phase 1b/2 trial for EP-104GI in EoE and explores new indications.
- Investor Sentiment
- How the market reacts to Eupraxia's presentation and 1x1 meetings at the Jefferies conference.
- Technology Validation
- Whether Diffusphere™ technology can demonstrate sustained efficacy and safety in broader applications.
Related topics